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Host-directed therapeutics present a new strategy to combat antibiotic resistance. We 
discovered a molecule, D8, that inhibits intracellular growth of Francisella tularensis in cell 
culture and mouse studies. However, the limited solubility of D8 leads to variability in dosing and 
the mechanism of action of D8 is unknown. Consequently, the objectives of this study are to 
increase the solubility of D8 utilizing salt formation and -cyclodextrin derivatives, as well as, 
identification of proteins that interact with D8 through chemoproteomics experiments. 
Methods 
Absorbance-based solubility assay. An absorbance-based solubility assay was developed 
based on our observation of increased absorbance above 400 nm for D8 aggregates. When D8 
is completely soluble, the absorbance at 400 nm is close to the baseline value. However, once 
D8 reaches saturation state, the absorbance intensity increases linearly with concentration.     
Identification of D8-interacting proteins. D8-33 and D8-34 are D8 and D8-05 (inactive analog of 
D8) derivatives with a diazirine group and a terminal alkyne. J774 cells were incubated with 
either D8-33 or D8-34. After incubation, the cells were illuminated at 365 nm to crosslink D8-33 
or D8-34 with its interacting proteins. After cell lysis, the cell lysate was conjugated with biotin-
N3 through click reaction and the resulting labeled proteins were subsequently enriched with 
streptavidin-coated resins for proteomics studies. 
Results 
Methyl--cyclodextrin substantially increases the solubility of D8 from 0.03 mM to 2.9 mM, 
enabling the delivery of D8 within 100 l PBS to reach dosage of 5 mg/kg for mouse studies. 
Captisol® and (2-hydroxypropyl)--cyclodextrin increase the solubility of D8 to 0.19 mM and 0.61 
mM, respectively. In contrast, salt formations do not significantly increase D8’s solubility. We 
also optimized the conditions for click reactions to couple D8-interacting proteins with biotin-N3.  
Conclusion 
We developed a formulation that enhances D8’s solubility by 100 times, enabling accurate 
dosing for animal studies. To identify D8-interacting proteins, we modified “click” reaction 
protocols. Further chemoproteomic studies should be completed to provide a list of potential D8-
interacting proteins to provide not only more insight into the mechanism of D8’s antibacterial 
activity, but also new therapeutic targets for future drug discovery. 
Introduction 
Antibiotic resistance has posed an economical and health burden to the U.S. population 
and health care system, accounting for $20 billion and approximately 70,000 deaths each 
year.1,2 This issue is even more pressing because new targets for antibacterial growth are 
lacking and the economic appeal of antibiotic development is low due to inevitable emergence 
of resistance.1 An issue with traditional antibiotics is that these drugs target pathogen specific 
properties such as cell wall biosynthesis and bacterial specific ribosomes for protein 
biosynthesis inhibition, making them active against limited groups of pathogens and susceptible 
to antibiotic resistance arising from bacterial mutations. Due to the rapid proliferation rate of 
bacteria, mutations are common in bacterial infections, with an average of 1 thousand mutations 
in 1010 bacteria, making them highly susceptible to developing a phenotypic mutation that 
renders a bacterium resistant against the antibiotic treatment.3 The resistant bacterial strain 
proliferates in the absence of antibiotic susceptible bacteria, resulting in subsequent antibiotic 
resistant bacterial infections.  
Various strategies have been implemented to combat antibiotic resistance. Specific 
examples include: i) modification of compound moieties that are targets of bacterial enzymes 
and efflux pumps; ii) development of adjuvant antibiotics to target antibiotic-destroying 
hydrolases; iii) screening for small molecules that are active against resistant strains; iv) 
development of new structural classes of antibiotics; v) identification of new bacteria specific 
targets for antibacterial growth; and vi) inhibition of bacterial gene targets that encode for 
enzymes that are essential for virulence and survival.3,4,5,6 These strategies are only temporarily 
effective because they are highly susceptible to bacterial resistance due to the focus on 
targeting bacterial components and high incidence of bacterial mutations. Host-directed 
therapies offer immunity to antibiotic resistance due to shifting from pathogen targets to host-
pathogen interactions.  
Host-directed therapies modulate immune responses and host defense mechanisms to 
enhance cellular responses to pathogens and improve therapeutic outcomes.7 The ability of 
host-directed therapies to suppress or enhance immune function make them potential strategies 
for prevention and treatment of infections through inhibition of pathogen invasion, replication, 
and proliferation. This approach for antibiotic development has many advantages, including 
prevention of antibiotic resistance and development of an antibiotic with broad-spectrum 
antimicrobial activity. Through targeting the host rather than pathogen mechanisms, there is no 
selective pressure for the development of antibiotic resistance.8, 9 In addition, it fosters a broad 
range of protection against various classes of microbes due to the non-specificity of innate and 
adaptive immunity.8 This enables prophylactic antibiotic use in high-risk groups, and empiric 
treatment, resulting in better therapeutic outcomes due to timeliness of administration of 
therapy.8 These host-directed antimicrobial approaches provide new targets for improved 
treatment of drug resistant pathogens. 
In collaboration with Dr. Tom Kawula’s lab at Washington State University, we have 
developed a small molecule, D8 (Fig. 1A), that inhibits the intracellular growth of Francisella 
tularensis in mouse bone marrow derived macrophages (Fig. 1B), with an IC50 value of 0.21 M. 
A structurally related analog, D8-05 (Fig. 1A), has no inhibitory effect and serves as a negative 
control. Importantly, D8 does not show toxic effect on host cells alone or inhibit bacteria growth 
outside host cells suggesting that it functions through mediating host-specific pathways. 
Intracellular growth of two other bacterial pathogens, Listeria monocytogenes and  
Campylobacter, is also inhibited by D8. Furthermore, mice infected with F. tularensis showed up 
to 10% weight loss and rapid bacterial growth in lung, liver, and spleen three days after 
inoculation. In contrast, those treated with D8 in phosphate buffered saline (PBS) with 5% 
DMSO maintained their weight although the bacterial growth is only inhibited in the liver. The 
lack of efficiency to control bacterial growth is likely due to the poor solubility of D8 in PBS. 
Additionally, the poor solubility of D8 contributes to variability of mice study results. Mice 2 and 3 
reached clinical cure indicated by inhibition of bacterial growth (Fig. 1C). However, mouse 1 
exhibited significant bacterial growth. A factor contributing to the variability in mouse study 
results is the variation in the concentration of D8 each mouse received in each dose, due to the 
precipitation of D8 in the syringe prior to intravenous injection. Consequently, there is a need for 
methods to enhance the solubility of D8.  
Figure 1. D8 is a novel host-targeting antibiotic compound.  
A. Chemical structures of D8 and its analog D8-05. D8-05 is the negative control 
for D8. It is structurally similar with no biological activity. B. Activity of D8 in 
macrophage cells post infection. Inhibition of bacterial growth in mice 
macrophage cells is represented by the absence of green fluorescence seen in the 
treatment group that received D8. C. Bacterial growth in mice infected with F. 
tularensis and treatment with either D8 in PBS or PBS (control). Mouse 2 and 3 
exhibited significant reductions in bacterial burden. However, this effect was not 
seen in mouse 1.    
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Despite the promise of further developing D8 as a host-targeting antibiotic, its 
mechanism of action is still unknown. Further research needs to be conducted to explore other 
potential targets for host-directed therapeutics and to investigate the potential benefits of these 
therapies in combination with traditional antibiotics for more effective infectious disease 
treatment. This highlights the importance of identifying the protein that D8 interacts with through 
pulldown experiments, as further investigation of D8 can provide additional information 
regarding new potential targets for host-directed therapies. 
Herein we report the development of a new formulation to increase D8’s solubility and a 
chemoproteomics approach to identify D8-interacting proteins.  
Methods 
β-cyclodextrin Formulations 
(2-Hydroxypropyl)-β-cyclodextrin (HBC). To measure the solubility of D8 in HBC-
containing buffer, 50% HBC in H2O (600 μL) was mixed with D8 in DMSO (50 μL) at various 
concentrations, 10x PBS (100 μL), and water (250 μL) at room temperature, with 2 cycles of 
vortexing for 1 min and sonication for 5 min. Each sample contained 30% HBC, 5% DMSO, and 
various concentrations of D8 (0.3, 0.6, 0.8, 1, and 1.5 mM). The absorbance of each sample 
was measured at the wavelength of 400 nm utilizing SmartSpec™3000 Spectrophotometer 
manufactured by Bio-Rad Laboratories. The absorbance values were plotted against D8 
concentration to obtain the calibration curve used to determine the solubility of D8 in 30% HBC, 
5% DMSO in PBS. The maximum solubility of D8 for the formulation was determined by 
calculating the D8 concentration at the intersection point of the two linear functions obtained 
from the concentration versus absorbance data prior to and after saturation of D8 in the vehicle. 
This absorbance-based solubility assay was developed based on our observation of increased 
absorbance at 400 nm for D8 aggregates, which are observed when the D8 concentration 
exceeded saturation of D8 in the vehicle. When D8 is completely soluble, the absorbance at 400 
nm is close to the baseline value. Likewise, the solubility of D8 in PBS containing 20% HBC and 
10% DMSO or 5% DMSO only (without HBC) was measured. Samples of 20% HBC, 10% 
DMSO in PBS were prepared with various D8 concentrations (0.04, 0.2, 0.4, 0.6, 0.8, 1.0, and 
1.5 mM). Similarly, samples of 0% HBC, 5% DMSO in PBS were prepared with D8 
concentrations of 0.001, 0.01, 0.02, 0.03, 0.1, and 0.2 mM to determine the effects of HBC 
concentration on the solubility of D8. To determine the effects of DMSO on the solubility of D8, 
samples of 30% HBC, 10% DMSO in PBS with 1 mM or 1.5 mM D8 and samples of 20% HBC, 
5% DMSO in PBS with 0.5 mM or 0.6 mM D8 were prepared in a similar manner.  
Methyl-β-cyclodextrin (MBC). To measure solubility of D8 in MBC-containing buffer, 50% 
MBC in water (600 μL) was mixed with D8 in DMSO (50 μL) at various concentrations, 10x PBS 
(100 μL) and water (250 μL) at room temperature, with 2 cycles of vortexing for 1 min and 
sonication for 5 min. Each sample contained 30% MBC and 5% DMSO, and various 
concentrations of D8 (0.6, 0.8, 1.0, 1.2, 1.5, 1.78, 2.0, 3.0, 4.0, and 5.0 mM). The absorbance of 
each sample was measured, and the calibration curve was obtained by the same methods as 
stated above. 
Captisol® (sulfobutylether-β-cyclodextrin). To measure solubility of D8 in Captisol®-
containing buffer, 50% Captisol® in H2O (600 μL) was mixed with D8 in DMSO (50 μL) at 
various concentrations, 10x PBS (100 μL), and water (250 μL) at room temperature, with 2 
cycles of vortexing for 1 min and sonication for 5 min. Each sample contained 30% Captisol®, 
5% DMSO, and various concentrations of D8 (0.1, 0.2, 0.3, 0.6, 0.8, and 1 mM). The 
absorbance of each sample was measured, and the calibration curve was obtained by the same 
methods as stated above. 
Salt Formation 
Starting with 500 L of 2.5 mM D8 in 25% DMSO and 75% water, 1 M concentration of 
sulfuric acid, hydrobromic acid, phosphoric acid, citric acid, L-tartaric acid, and L-lactic acid 
were added in 3 increments of 500 uL to determine the effect of various acids of on the solubility 
of D8. The absorbance of each sample was measured by the same method as stated above.  
Identification of protein targets of D8 utilizing click reaction and pull down experiments 
J774 cells were treated with either D8-33 (100 M) or D8-34 (100 M) in serum-free 
Dulbecco’s Modified Eagle Medium (DMEM) at 37 oC in an incubator with 5% CO2 for 30 min. 
D8-33 is a D8 derivative incorporated with a photoactivatable diazirine group and a terminal 
alkyne. Likewise, D8-34 is the corresponding derivative of D8-05, a structurally similar but 
inactive analog of D8. After removal of the culture medium, the cells were illuminated with light 
at 365 nm for 15 min to crosslink D8-33 or D8-34 with its interacting proteins. The cells were 
then washed with cold phosphate-
buffered saline (PBS) twice and 
harvested by scratching off the 
plate with cold PBS. The cell 
pellets were collected by 
centrifugation at 14,000g for 5 min. 
To lyse the cells, PBS with 0.1% 
NP-40 and protease inhibitors was 
added to re-suspend the pellet by 
passing the suspension through a 
27G needle 10 times. The 
supernatant was collected after 
the mixture was centrifuged at 
14,000g for 10 min as cell lysate 
fraction 1. The resulting cell pellets 
were then resuspended with PBS 
with 1.0% NP-40 and the 
corresponding supernatant is cell 
lysate fraction 2. Each fraction of 
cell lysate (500 μL) was 
conjugated with biotin-N3 through 
click reaction (0.1 mM BTTAA, 0.1 
mM biotin-N3, 1 mM CuSO4, 1 mM 
ascorbic acid, 1 mM TCEP, 
flushed with N2 for 1 min, 
incubated at 37 oC for 4.5 h) and 
the proteins were subsequently 
precipitated with 4:1 
methanol/chloroform (2500 μL) 
and PBS (1000 μL) to form a 
Figure 2. Absorbance of D8 in formulations with 
various β-cyclodextrins (30%). The maximum 
solubility of D8 in 30% Captisol, 30% HBC, and 30% 
MBC are 0.19 mM, 0.61 + 0.06 (SD) mM, and 2.9 + 
0.13 (SD) mM respectively. The maximum solubility of 
D8 in each formulation was determined by calculating 
the D8 concentration at the intersection point of the two 
linear functions obtained from the concentration versus 
absorbance data prior to and after saturation of D8 in 
the vehicle. The standard deviations were determined 
by measuring the absorbance values of the samples at 































protein disc. The organic and aqueous layers were pipetted out and discarded after 
centrifugation (10 min). The protein disc was washed 3 times with 1:1 methanol/chloroform 
(1000 μL) and subsequently, 4:1 methanol/chloroform (3000 μL) was added and the sample 
was sonicated (1 min) and centrifuged (10 min). Then, the supernatant was discarded and PBS 
(800 μL) with 1% SDS and 1x protease inhibitor was added and subsequently incubated with 
Dynabead (streptavidin column) at 4 oC for 1.5 h. After immobilization of the streptavidin column 
with DynaMagTM-spin magnet, the supernatant was pipetted off as flow through. The beads 
were then washed with 0.5% NP-40 PBS (400 μL) three times. The interacting proteins were 
eluted by adding 3 mM biotin-N3 0.5% NP-40 PBS (200 μL) and heating the beads at 95 oC for 
20 min (repeated for elution 2). 
Results 
β-cyclodextrin Formulations 
The absorbance values were plotted against D8 concentration to obtain the calibration 
curve used to determine the solubility of D8 in each β-cyclodextrin formulation. Based on the 
calibration curves, the maximum solubility of D8 in 0% HBC, 30% Captisol, 30% HBC, and 30% 
MBC are 0.03 mM, 0.19 mM, 0.61 + 0.06 mM, and 2.9 + 0.13 mM respectively (Fig. 2). Based 
on this data, 30% MBC has shown to increase the solubility of D8 by 100 fold, from 0.03 mM to 
2.9 + 0.13 mM.  
Additionally, the effect of DMSO concentration on D8 and HBC were analyzed (Fig. 3). 
Comparing 0.6 mM D8 in 20% 
HBC, 5% DMSO and 20% HBC, 
10% DMSO, the absorbance 
values are 0.28 and 0.36, 
respectively. Comparing 1.5 mM 
D8 in 30% HBC, 5% DMSO and 
30% HBC, 10% DMSO, the 
absorbance values are 0.46 and 
1.10, respectively. The increase in 
absorbance at 10% DMSO 
compared to 5% DMSO indicates 
that as the concentration of DMSO 
increases, the solubility of D8 in 
HBC decreases.  
Additional analysis was 
conducted to determine the effect 
of HBC concentration on the 
solubility of D8 (Fig. 4). The 
maximum solubility of D8 in 0% 
HBC, 5% DMSO; 20% HBC, 10% 
DMSO; and 30% HBC, 5% DMSO 
are 0.03 mM, 0.41 mM and 0.61 + 
0.06 mM respectively. This 
indicates that increasing the 
Figure 3.  Absorbance of D8 in formulations with 
various concentrations of (2-Hydroxypropyl)-β-
cyclodextrin and DMSO formulations. DMSO 
negatively impacts the solubility of D8. An increase in 
DMSO concentration decreases the solubility of D8 in 
HBC formulations. This is represented by the increase 
in absorbance values when the concentration of 

























concentration of HBC significantly 
increases the solubility of D8. 
 
Salt Formation 
The effect of salt formation 
on the solubility of D8 was 
evaluated qualitatively and 
quantitatively utilizing 
spectrophotometry following each 
incremental addition of 500 μLof 1 
M acid to 500 μL of 2.5 mM D8 in 
25% DMSO and 75% water. Both 
strong and weak acids were used 
in this set of experiments and the 
corresponding absorbance of 
various acids with the addition of 0 
μL, 500 μL, 1000 μL, and 1500 μL 
of various acids were measured 
(Fig. 5). Addition of 1500 μL of 1 M 
sulfuric acid, hydrobromic acid, 
phosphoric acid, citric acid, L-
tartartic acid, and L-lactic acid 
changed the absorbance from 1.09 
to 1.69, 1.23 to 1.50, 1.56 to 0.55, 
1.98 to 0.49, 1.85 to 0.68, and 1.92 
to 0.66, respectively. As the 
volume of acid added increased, 
the absorbance values decreased, 
but did not reach the baseline of 0.  
Identification of protein targets of 
D8 utilizing click reaction and pull 
down experiments 
Optimization of click reaction  
“Click” reaction is the 
copper-catalyzed [3+2]-cyclization 
between an azide and an alkyne 
and has been widely used in 
biological applications. To identify 
D8-interacting proteins, we 
developed a D8 analog, D8-33 
(Fig. 6A), with a diazirine and an 
alkyne group incorporated. The 
diazirine group was introduced to 
Figure 4. Absorbance of D8 in formulations with 
various concentrations of (2-Hydroxypropyl)-β-
cyclodextrin. Increasing the concentration of HBC 
increases the solubility of D8. The maximum solubility 
of D8 in 0% HBC, 5% DMSO; 20% HBC, 10% DMSO; 
and 30% HBC, 5% DMSO are 0.03 mM, 0.41 mM and 
0.61 + 0.06 (SD) mM respectively.  

























30% HBC, 5% 
DMSO
20% HBC, 10% DMSO
0% HBC, 5% 
DMSO
Figure 5. Absorbance at various volumes of 
various acids added to 500 μL of 2.5 mM D8 in 25% 
DMSO, 75% water. Salt formulations were ineffective 
in significantly enhancing the solubility of D8, as 
evidenced by the presence of visible precipitation in the 
samples, and absorbance > 0, even with substantial 
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crosslink with D8-interacting proteins in live cells upon light illumination. The alkyne group is 
used for “click” reaction, which leads to the addition of the biotin-N3 functional group used for 
pull down experiments. The negative control, D8-34 is a derivative of D8-05.  
To optimize the conditions for “click” reaction between crosslinked D8-interacting 
proteins and 6-FAM-N3, we varied the concentration of various components involved in the 
reaction including CuSO4, reducing agent, and 6-FAM-N3. In addition, we also investigated the 
effects of reaction time and temperature. 6-FAM- N3 was used instead of biotin-N3 in 
optimization of click reaction experiments due to its ability to be visualized on sodium dodecyl 
sulfate polyacrylamide gel 
electrophoresis (SDS-PAGE) 
without dye. The reaction efficiency 
was measured by fluorescence 
intensity of 6-FAM-N3-labeled 
proteins on a gel. The optimal 
reaction conditions were 
determined. Briefly, D8-crosslinked 
proteins were mixed with 0.1 mM 
BTTAA, 0.1 mM 6-FAM-N3, 1 mM 
CuSO4, 1 mM ascorbic acid, and 1 
mM TCEP at room temperature. 
The resulting mixture was flushed 
with N2 for 1 min and incubated at 
37oC for 4.5 h. The proteins in the 
reaction were then resolved 
through SDS-PAGE and detected 
by fluorescence. One 
representative image is shown in 
Fig. 6B.   
Identification of D8 interacting 
proteins 
Utilizing the optimized 
“click” reaction conditions, the 
pulldown experiment was next 
conducted. In this experiment, 
biotin-N3 was used in place of 6-
FAM-N3 to label crosslinked D8-
interacting proteins. The 
biotinylated proteins were then 
bound to streptavidin-coated 
Dynabead. The non-specific 
interacting proteins were first 
washed out. The D8-interacting 
proteins were then eluted with 
biotin (3 mM) at 95 oC. As shown in 
Fig. 7, specific bands of proteins 
Figure 6. Target identification of D8.  
A. Crosslinking and affinity tag labeling of D8-
interacting proteins. To identify D8-interacting 
proteins, we developed a D8 analog, D8-33, and the 
negative control, D8-34, with a diazirine and an alkyne 
group incorporated. The diazirine group is utilized to 
crosslink with D8-interacting proteins in live cells upon 
light irradiation. The alkyne group then underwent 
“click” reaction, which led to the addition of the biotin-N3 
functional group used for pull down experiments.  
B. SDS-PAGE of the cell lysates labeled with 6-
FAM-N3. Fraction 1 represents cell lysates with 0.1% 
NP-40 PBS while fraction 2 represents cell lysates with 
1% NP-40 PBS. Optimal click reaction conditions were 
identified and supported by high fluorescence intensity 
visualized via SDS-PAGE. High fluorescence intensity 
shown in both fractions of samples D8-33 and D8-34 
correlates with high reaction efficacy and significant 6-




are visualized in the sample resulting from D8-33, but not D8-34, suggesting that affinity 
chromatography is effective in eluting D8 interacting proteins. The eluted proteins were sent to 
the proteomics core for identification.   
Discussion 
β-Cyclodextrin Formulations 
β-cyclodextrins are effective in enhancing solubility through incorporation of hydrophobic 
drugs inside the cylindrical shape and the presence of a hydrophilic exterior enabling it to be 
soluble in water. Based on the results, absorbance values are in the order of tenths of 
thousandths to hundredths of thousandths when D8 is completely solubilized. This indicates an 
absorbance of essentially 0 (baseline) when D8 is 
completely solubilized. This is further supported by the 
absence of visible precipitation in solution. However, as the 
concentration of D8 increases and the maximum solubility 
of D8 in the vehicle is reached, the absorbance values 
increase drastically and D8 forms visible aggregates. 
Additionally, when samples were centrifuged to remove the 
precipitation, the absorbance returned to baseline, 
confirming that absorbance at 400 nm corresponds to D8 
aggregation.   
All three cyclodextrin derivatives substantially 
increase the solubility of D8. Most strikingly, MBC 
formulation effectively increased the solubility of D8 by 100-
fold from 0.03 mM to 2.9 + 0.13 mM. The low solubility of 
D8 in PBS leads to the precipitation of D8 in 2.7 mM D8 in 
the PBS formulation used for animal studies. This 
precipitation of D8 in PBS was attributed to the variation in 
animal study data through variations in IV dosing. 
Therefore, effective solubilization of 2.7 mM D8 with the 
MBC formulation provides accurate IV dosing for animal 
studies. Elimination of variations in animal study data will 
provide further insight on D8’s biological effect in inhibition 
of F. tularensis growth.  
The effect of DMSO concentration on HBC 
formulations were investigated by comparing 5% and 10% 
DMSO concentrations in 30% and 20% HBC. The results 
indicate that increasing the DMSO concentration impacts 
D8-β-cyclodextrin interactions, decreasing the solubility of 
D8 in β-cyclodextrin formulations (Fig. 3). While DMSO 
cannot be eliminated in the formulation, the concentration of 
DMSO should be minimized. DMSO in the formulation 
cannot be eliminated due to difficulty in solubilizing solid D8 in 30% HBC and can be attributed 
to a limitation of this study. In order to easily prepare formulations of D8 in β-cyclodextrin, D8 in 
DMSO was added to 50% β-cyclodextrin stock solution, 10x PBS, and water to obtain a 
formulation of D8 in 30% β-cyclodextrin, 5% DMSO in PBS. 
Figure 7. Pulldown 
experiment results using 
optimized click reaction 
conditions. Specific bands of 
proteins are visualized in the 
sample resulting from D8-33, 
but not D8-34, suggesting that 
affinity chromatography is 
effective in eluting D8 




The effect of HBC concentration on the solubility of D8 was also investigated by 
comparing 0%, 20%, and 30% HBC concentrations. Increase in HBC concentration significantly 
increased the solubility of D8. Therefore, further increase in HBC concentration will likely further 
increase the solubility of D8. However, the concentration of β-cyclodextrin is limited by renal 
toxicity.10,11 The LD50 of β-cyclodextrin for IV dosing in rats is 788 mg/kg.12 In comparison, the β-
cyclodextrin concentration in 2 mL of 30% β-cyclodextrin D8 formulation is 600 mg. Further 
increasing the concentration of β-cyclodextrin could lead to toxicity in animal studies. 
An advantage of this approach is that enhanced solubility is achieved through specific 
interactions rather than changes to the structural properties of the small molecule, thereby 
preserving the biological activity of D8. Limitations include limits on the concentration of β-
cyclodextrin in the formulations and the inconsistent concentrations of DMSO between the 30% 
HBC, 5% DMSO and 20% HBC, 10% DMSO formulations. Due to this inconsistency, we are not 
able to quantitatively determine the degree of increase in solubility between 20% HBC and 30% 
HBC formulations (Fig 4). However, the conclusion that increasing the concentration of HBC 
increases the solubility of D8 is valid based on the increase in the solubility of D8 in 30% HBC, 
5% DMSO compared to 20% HBC, 5% DMSO from 0.5 mM to 0.6 mM (Fig 3).  
These results were consistent with a study investigating the solubility of aromatic small 
molecules: hydrocortisone, diazepam, digitoxin, and indomethacin in various modified β-
cyclodextrins. MBC formulations resulted in the greatest increase in solubility of these small 
molecules.13 Future research should focus on conducting animal studies with MBC-D8 
formulation to accurately evaluate the effect of D8 for inhibition of F. tularensis facilitated by 
accurate IV dosing of D8.  
Salt Formation 
Salt formations were utilized to enhance the solubility of D8 due to the preservation of 
D8’s structure and the cost effectiveness of this approach. We hypothesized that the pyridine 
functional group (pKa 5.25) of D8 will easily form salts with the selected acids, thereby 
increasing solubility.  
Salt formulations were ineffective in significantly enhancing the solubility of D8, as 
evidenced by the presence of visible precipitation in the samples, and absorbance > 0, even 
with substantial volumes of acid added (Fig. 5). The decrease in absorbance with each 500 μL 
increment of acid added to the samples is attributed to the effect of dilution because increasing 
the volume of acid did not decrease the amount of visible precipitation in the samples. These 
results differed from findings in other salt formation solubility studies of aromatic small 
molecules. A study conducted by Bastin, et al. investigated salt formations for increasing the 
solubility of a weak base with a pKa of 5.3 and a poor aqueous solubility of 10 μg/mL. This 
compound formed stable salts with hydrochloride and hydrobromide counterions, with solubility 
values of 16.68 mg/mL and 3.29 mg/mL respectively.14 
Strengths of this approach include the cost effectiveness and preservation of the 
chemical structure of the parent molecule. Limitations include unacceptable high acidity in 
formulations for IV dosing, breakdown of parent molecule in high acidity, and dilution effect of 
adding large volumes of acid to D8. The dilution effect limits the ability to accurately quantify the 
effect of various acids on the solubility of D8. However, due to absorbance values > 0 and the 
presence of visible precipitation, we can conclude that salt formation did not significantly 
increase the solubility of D8. 
Identification of protein targets of D8 utilizing click reaction and pull down experiments  
Optimization of click reaction 
Optimal click reaction conditions (0.1 mM BTTAA, 0.1 mM 6-FAM-N3, 1 mM CuSO4, 1 
mM ascorbic acid, and 1 mM TCEP, flushing with N2 for 1 min, incubated at 37oC for 4.5 h.) 
were identified and supported by high fluorescence intensity visualized via SDS-PAGE (Fig.6B). 
High fluorescence intensity correlates with high reaction efficacy and increased 6-FAM-N3 
labeled proteins. Successful optimization of click reaction conditions enables efficient generation 
of biotin-N3 labeled D8 interacting proteins for high specificity elution of D8 interacting proteins 
utilizing streptavidin beads. 
The optimal click reaction conditions were determined by investigating the different 
components involved (6-FAM-N3 concentration, ascorbic acid concentration, reaction time, 
reaction temperature, and with or without flushing with N2 for 1 min).  A reaction time of 4.5 h 
was chosen because longer reaction times lead to increased protein degradation likely due to 
the generation of reactive oxygen species and shorter reaction times lead to decreased intensity 
of proteins labeled with 6-FAM-N3. Degassing with N2 is suspected to decrease the formation of 
reactive oxygen species and therefore decrease protein degradation. A potential limitation to 
this study is that this hypothesis was not formally tested to quantify the effects of degassing on 
protein degradation. Another method to decrease reactive oxygen radical species during the 
reaction is to use a reducing reagent, ascorbic acid. However, the click reaction experiments 
investigating 0 mM vs 1 mM ascorbic acid and 37oC vs room temperature were inconclusive. 
Differences in 6-FAM-N3 labeled protein intensity could not be determined because the 
fluorescence intensity of 6-FAM-N3 labeled protein in the all samples were too low to detect 
differences in fluorescence intensity between samples. Therefore, the results were confounded 
by inefficiency in 6-FAM-N3 labeling. The effects of ascorbic acid and reaction temperature on 
protein degradation cannot be visualized due to low protein yield. Therefore, this is considered a 
limitation. Increased 6-FAM-N3 concentration (0.025 mM vs 0.1 mM) yielded higher 
fluorescence intensity in 6-FAM-N3 labeled proteins due to more complete reaction. Further 
studies need to be conducted to quantify the impact of 1 mM ascorbic acid, degassing with 
nitrogen, and reaction temperature on protein degradation during click reaction.  
These results differed from click reaction results in other studies. Click reaction 
conditions utilized by Parker et al (0.1 mM TBTA, 1 mM CuSO4, 25 μM TAMRA-N3, and 1 mM 
TCEP) and Hӧglinger et al (2.5 mM TBTA, 25 mM CuSO4, 25 mM biotin-N3, and 25 mM 
ascorbic acid) were effective for affinity tag labeling of proteins.15,16 However, these click 
reaction conditions are not optimal for our small molecule.  
Identification of D8 interacting proteins 
 Affinity chromatography with streptavidin-coated Dynabead is effective in enriching 
biotinylated D8-interacting proteins, indicated by visualization of specific bands of proteins in the 
sample derived from D8-33, but not that from D8-34 (Fig. 7). D8-34 is the negative control 
because it was determined to have no inhibitory activity. Proteins that interact with both D8-33 
and D8-34 are considered non-contributory to inhibition of bacterial growth by D8. Eluted D8-
interacting proteins were sent to proteomics core for identification. These results were 
consistent with experiments conducted by Kimble et al, which showed successful elution of 
biotin-N3 labeled proteins using streptavidin beads.17 Strengths of this approach include tight 
interaction between biotin and streptavidin (Kd ~10-15 M) enabling stringent washing and 
resulting in low amounts of non-interacting proteins. Furthermore, light-induced photo-affinity 
labeling forms a covalent bond between D8 and its interacting protein targets. This crosslinking 
enables elution of both strong and weak D8 interacting proteins. One limitation of this approach 
is the potential for inefficient elution of D8 interacting proteins from the streptavidin affinity 
column due to the tight interaction between biotin-N3 and streptavidin. Therefore, further 
research needs to be conducted to compare the efficiency of D8 interacting protein elution using 
3 mM biotin-N3 in buffer with 0.5% NP-40 PBS compared to the utilization of trypsin digestion to 
dissociate D8 interacting proteins from the streptavidin column. Identification of a list of potential 
D8-interacting proteins will provide more insight into the mechanism of D8’s antibacterial 
activity, and new therapeutic targets for future drug discovery. 
Conclusion 
In conclusion, we developed a formulation that enhances D8’s solubility by 100 times, 
thereby, enabling accurate dosing for animal studies. Future animal studies with accurate D8 
dosing will provide less data variability and more insight on the efficacy of D8 as a host-directed 
antibiotic. To identify D8-interacting proteins, we optimized click reaction protocols. This enables 
efficient generation of D8-interacting proteins labeled with biotin-N3, which will be subsequently 
enriched utilizing streptavidin beads. Further chemoproteomic studies should be completed to 
provide a list of potential D8-interacting proteins to not only provide more insight into the host-
directed mechanism of D8’s antibacterial activity, but also new therapeutic targets for future 
drug discovery. Future development of host-directed antimicrobials provides a new strategy for 
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